Kalbe Farma
Market Cap
Rp68.9t
Last Updated
2021/05/10 17:18 UTC
Data Sources
Company Financials +
Executive Summary
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with proven track record and pays a dividend.
Similar Companies
Share Price & News
How has Kalbe Farma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KLBF is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: KLBF's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
0%
KLBF
1.3%
ID Pharmaceuticals
-0.5%
ID Market
1 Year Return
6.1%
KLBF
20.4%
ID Pharmaceuticals
22.3%
ID Market
Return vs Industry: KLBF underperformed the ID Pharmaceuticals industry which returned 20.4% over the past year.
Return vs Market: KLBF underperformed the ID Market which returned 22.3% over the past year.
Shareholder returns
| KLBF | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 1.3% | -0.5% |
| 30 Day | -5.2% | -3.8% | -2.7% |
| 90 Day | -3.6% | -9.1% | -5.5% |
| 1 Year | 8.1%6.1% | 22.7%20.4% | 26.3%22.3% |
| 3 Year | 12.4%6.1% | 2.3%-3.3% | 2.3%-5.4% |
| 5 Year | 23.1%13.1% | 32.9%20.3% | 34.1%17.8% |
Long-Term Price Volatility Vs. Market
How volatile is Kalbe Farma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Kalbe Farma undervalued compared to its fair value and its price relative to the market?
25.21x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: KLBF (IDR1470) is trading above our estimate of fair value (IDR938.74)
Significantly Below Fair Value: KLBF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: KLBF is poor value based on its PE Ratio (25.2x) compared to the ID Pharmaceuticals industry average (25x).
PE vs Market: KLBF is poor value based on its PE Ratio (25.2x) compared to the ID market (22.4x).
Price to Earnings Growth Ratio
PEG Ratio: KLBF is poor value based on its PEG Ratio (3.4x)
Price to Book Ratio
PB vs Industry: KLBF is overvalued based on its PB Ratio (4x) compared to the ID Pharmaceuticals industry average (2.4x).
Future Growth
How is Kalbe Farma forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
7.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KLBF's forecast earnings growth (7.5% per year) is above the savings rate (7.2%).
Earnings vs Market: KLBF's earnings (7.5% per year) are forecast to grow slower than the ID market (21.4% per year).
High Growth Earnings: KLBF's earnings are forecast to grow, but not significantly.
Revenue vs Market: KLBF's revenue (6.5% per year) is forecast to grow slower than the ID market (10.7% per year).
High Growth Revenue: KLBF's revenue (6.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KLBF's Return on Equity is forecast to be low in 3 years time (16%).
Past Performance
How has Kalbe Farma performed over the past 5 years?
5.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KLBF has high quality earnings.
Growing Profit Margin: KLBF's current net profit margins (11.8%) are higher than last year (11.1%).
Past Earnings Growth Analysis
Earnings Trend: KLBF's earnings have grown by 5% per year over the past 5 years.
Accelerating Growth: KLBF's earnings growth over the past year (9%) exceeds its 5-year average (5% per year).
Earnings vs Industry: KLBF earnings growth over the past year (9%) underperformed the Pharmaceuticals industry 9%.
Return on Equity
High ROE: KLBF's Return on Equity (15.3%) is considered low.
Financial Health
How is Kalbe Farma's financial position?
Financial Position Analysis
Short Term Liabilities: KLBF's short term assets (IDR13,075.3B) exceed its short term liabilities (IDR3,176.7B).
Long Term Liabilities: KLBF's short term assets (IDR13,075.3B) exceed its long term liabilities (IDR1,111.5B).
Debt to Equity History and Analysis
Debt Level: KLBF's debt to equity ratio (5.8%) is considered satisfactory.
Reducing Debt: KLBF's debt to equity ratio has increased from 3.6% to 5.8% over the past 5 years.
Debt Coverage: KLBF's debt is well covered by operating cash flow (395.6%).
Interest Coverage: KLBF earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Kalbe Farma current dividend yield, its reliability and sustainability?
1.77%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: KLBF's dividend (1.77%) is higher than the bottom 25% of dividend payers in the ID market (1.15%).
High Dividend: KLBF's dividend (1.77%) is low compared to the top 25% of dividend payers in the ID market (4.83%).
Stability and Growth of Payments
Stable Dividend: KLBF's dividend payments have been volatile in the past 10 years.
Growing Dividend: KLBF's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (44.6%), KLBF's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: KLBF's dividends in 3 years are forecast to be well covered by earnings (49.1% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.6yrs
Average management tenure
CEO
- Vidjongtius (56 yo)
3.92yrs
Tenure
Mr. Vidjongtius has been President Director of PT Kalbe Farma Tbk. since June 5, 2017. He served as Corporate Secretary of PT. Kalbe Farma Tbk. since March 28, 2008 until June 14, 2017. Mr. Vidjongtius ser...
Leadership Team
Experienced Management: KLBF's management team is seasoned and experienced (7.6 years average tenure).
Board Members
Experienced Board: KLBF's board of directors are considered experienced (5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
PT Kalbe Farma Tbk.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: PT Kalbe Farma Tbk.
- Ticker: KLBF
- Exchange: IDX
- Founded: 1966
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: Rp68.903t
- Shares outstanding: 46.87b
- Website: https://www.kalbe.co.id
Number of Employees
Location
- PT Kalbe Farma Tbk.
- Gedung KALBE
- Jl. Let. Jend. Suprapto Kav. 4
- Jakarta
- Jakarta Raya
- 10510
- Indonesia
Listings
Biography
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. It operates in four divisions: Prescription Pharmaceuticals, Consumer Health...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/10 17:18 |
| End of Day Share Price | 2021/05/10 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.